AKBA Stock Summary and Trading Ideas (Akebia Therapeutics | NASDAQ:AKBA)

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Akebia Therapeutics trades on the NASDAQ stock market under the symbol AKBA.

As of March 20, 2026, AKBA stock price climbed to $1.44 with 1,019,975 million shares trading.

AKBA has a beta of 0.35, meaning it tends to be less sensitive to market movements. AKBA has a correlation of 0.01 to the broad based SPY ETF.

AKBA has a market cap of $381.81 million. This is considered a Small Cap stock.

Last quarter Akebia Therapeutics reported $58 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $10 million and met earnings estimates .

In the last 3 years, AKBA traded as high as $4.08 and as low as $.49.

The top ETF exchange traded funds that AKBA belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWN.

AKBA has underperformed the market in the last year with a return of -49.3%, while the SPY ETF gained +16.3%. In the last 3 month period, AKBA fell short of the market, returning -13.3%, while SPY returned -4.2%. However, in the most recent 2 weeks AKBA has outperformed the stock market by returning +21.0%, while SPY returned -4.3%.

AKBA support price is $1.37 and resistance is $1.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA shares will trade within this expected range on the day.